Your browser doesn't support javascript.
loading
CD137L and CD4 T cells limit BCL6-expressing pre-germinal center B cell expansion and BCL6-driven B cell malignancy.
Ding, Zhoujie; Quast, Isaak; Yan, Feng; Liao, Yang; Pitt, Catherine; O-Donnell, Kristy; Robinson, Marcus J; Shi, Wei; Kallies, Axel; Zotos, Dimitra; Tarlinton, David M.
Afiliação
  • Ding Z; Department of Immunology and Pathology, Alfred Medical Research and Education Precinct, Monash University, Melbourne, VIC, Australia.
  • Quast I; Department of Immunology and Pathology, Alfred Medical Research and Education Precinct, Monash University, Melbourne, VIC, Australia.
  • Yan F; Australian Centre for Blood Diseases, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Liao Y; Olivia Newton John Cancer Research Institute, Melbourne, VIC, Australia.
  • Pitt C; Department of Immunology and Pathology, Alfred Medical Research and Education Precinct, Monash University, Melbourne, VIC, Australia.
  • O-Donnell K; Department of Immunology and Pathology, Alfred Medical Research and Education Precinct, Monash University, Melbourne, VIC, Australia.
  • Robinson MJ; Department of Immunology and Pathology, Alfred Medical Research and Education Precinct, Monash University, Melbourne, VIC, Australia.
  • Shi W; Olivia Newton John Cancer Research Institute, Melbourne, VIC, Australia.
  • Kallies A; School of Medicine, La Trobe University, Heidelberg, VIC, Australia.
  • Zotos D; The Peter Doherty Institute, University of Melbourne, Melbourne, VIC, Australia.
  • Tarlinton DM; Department of Immunology and Pathology, Alfred Medical Research and Education Precinct, Monash University, Melbourne, VIC, Australia.
Immunol Cell Biol ; 100(9): 705-717, 2022 Oct.
Article em En | MEDLINE | ID: mdl-35916066
ABSTRACT
Aberrant expression of the proto-oncogene BCL6 is a driver of tumorigenesis in diffuse large B cell lymphoma (DLBCL). Mice overexpressing BCL6 from the B cell-specific immunoglobulin heavy chain µ intron promoter (Iµ-Bcl6Tg/+ ) develop B cell lymphomas with features typical of human DLBCL. While the development of B cell lymphoma in these mice is tightly controlled by T cells, the mechanisms of this immune surveillance are poorly understood. Here we show that CD4 T cells contribute to the control of lymphoproliferative disease in lymphoma-prone Iµ-Bcl6Tg/+ mice. We reveal that this CD4 T cell immuno-surveillance requires signaling by the co-stimulatory molecule CD137 ligand (CD137L; also known as 4-1BBL), which may promote the transition of pre-malignant B cells with an activated phenotype into the germinal center stage via reverse signaling, preventing their hazardous accumulation. Thus, CD137L-mediated CD4 T cell immuno-surveillance adds another layer of protection against B cell malignancy to that provided by CD8 T cell cytotoxicity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Ligante 4-1BB Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Ligante 4-1BB Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article